Loading…
← CockpitCompetitor Analysis › 7716.T Nakanishi Inc.Open in the cockpit ↗

Nakanishi Inc.7716.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties

Japanese maker of dental handpieces and precision dental/medical equipment used by dentists worldwide.

≈ A dental-equipment specialist like a smaller Dentsply Sirona unitMomentum strong 75
Mkt cap
$1.78B
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$12.3M
20-day average traded
Fwd P/E
19.0×
forward earnings
ROIC−WACC
+6.3 pp
WACC 7.6%
Hurdle
-15 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · JPY¥1,601
1D+1.5%
1W+13.6%
1M+13.6%
3M-2.4%
6M+7.0%
YTD+61.6%
1Y+54.3%
ATR %3.6%
52w lowhigh5.4% off high

What Nakanishi does

Japanese maker of dental handpieces and precision dental/medical equipment used by dentists worldwide.

Sells high-speed handpieces under the NSK name mainly through dental distributors, with overseas markets together bigger than Japan, and earns from repairs and replacement as handpieces wear out.

In one line: A dental-equipment specialist like a smaller Dentsply Sirona unit.

Products and services

  • Dental handpieces
  • Dental treatment equipment
  • Medical precision motors

Customers

  • Dentists/dental clinics worldwide

Where it sits in the supply chain

  • Health care
  • Dental equipment
  • Dental handpieces, precision…

What could go right

  • Global dental procedure volume growth

What could go wrong

  • Dental clinic capex cyclicality

Moat: narrow (process know-how, brand). Precision micro-motor engineering and brand trust among dentists built over decades.

Headquarters: Tochigi, Japan · Founded: 1930 · Employees: 2,204

Named competitors

Nakanishi at a glance

Size Nakanishi (7716.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.78B, the 519th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,601 on 18 Nov 2026.

Performance Over six months the shares gained 7.0%, against +1.5% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 17.2% over the last twelve months (peer median +9.6%); the operating margin is 21.1% (peer median 12.7%).

Valuation It trades at 19.0× forward earnings against a peer median of 27.0× (6th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.3 points above its cost of capital (7.6% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 20267716.T 109Peer median 99
Six months, rebased to 100: Nakanishi against the median of its 20 peers (local-currency closes).

Nakanishi financials

Reported figures in JPY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥92.8B¥81.2B¥77.0B¥59.7B¥48.7B
Revenue growth—+5%+29%+23%—
Gross profit¥54.3B¥42.2B¥40.4B¥34.1B¥30.4B
EBITDA¥26.3B¥19.9B¥20.5B¥17.7B¥17.5B
Net income¥3.91B-¥2.40B¥8.58B¥22.8B¥12.5B
Free cash flown/a¥12.3B¥10.5B¥2.93B¥4.29B
Capital expendituren/a¥5.31B¥5.25B¥5.95B¥3.98B
Total debt¥30.7B¥26.8B¥18.7B¥11.7B¥481M

Quarterly statements and history in the cockpit →

Nakanishi competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%CHEMMPOLYMED1066LMAT6960301363268AEMBLASKANMEDKMTSINSP8086BFLY301087688531VITR7716.T6-month return →1-month return →
Up and to the right = strong over both horizons. Nakanishi is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×60×CHEMMPOLYMED1066LMAT6960301363268AEMBLASKANMEDXRAYINSP6699301087688531VITR7716.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Nakanishi is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%CHEMM1066LMAT6960301363268AEMBLASKANXRAYINSP6699301087VITR7716.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Nakanishi is the large dot.

Nakanishi competitors and peer comparison

Head to head with its named competitors (7716.T vs XRAY vs 6455.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Nakanishi 7716.T$1.78B+7%+17%21%19.0×4.8%
DENTSPLY SIRONA XRAY$1.69B-13%-1%5%6.8×11.2%
Morita 6455.T$666M-5%0%12%10.2×-11.8%

How Nakanishi compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Nakanishi against its 20 peers (data as of 18 Nov 2026)
Measure7716.TPeer medianRank in peer set
1-month return+13.6%-5.0%4th highest of 21
6-month return+7.0%+1.5%9th highest of 20
Distance from 52-week high-5.4%-24.8%2nd highest of 21
Revenue growth (TTM)+17.2%+9.6%9th highest of 21
Operating margin21.1%12.7%3rd highest of 21
Forward P/E19.0×27.0×6th cheapest of 18
Growth the price implies (Req g, 7 yrs)4.8%13.8%5th least demanding of 14
Growth delivered (Del g)+19.7%+12.7%4th highest of 14
Hurdle (Req g minus delivered)-14.9 pp-0.3 pp2nd least demanding of 14
ROIC minus cost of capital+6.3 pp-0.6 pp7th highest of 21
EV / EBITDA10.0×16.8×5th cheapest of 15
Net debt / EBITDA-0.8×-0.7×8th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%

Questions

Who are Nakanishi's main competitors?
Named competitors: Dentsply Sirona (XRAY), Morita Corp (6455.T). The cockpit's measured peer set (industry) also includes ChemoMetec A/S (CHEMM.CO), Poly Medicure (POLYMED.NS), Shandong Weigao Group Medical Polymer (1066.HK), LeMaitre Vascular (LMAT), Fukuda Denshi (6960.T), Mehow Innovative (301363.SZ).
Is Nakanishi expensive compared with its peers?
On forward p/e it trades at 19.0× against a peer median of 27.0×, 6th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has Nakanishi stock performed?
Over six months to 18 Nov 2026 the shares returned +7.0% against +1.5% for the median peer; over one year +54.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.